Literature DB >> 14610317

Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole.

Hideo Matsui1, Yoshinori Iitsuka, Koji Yamazawa, Naotake Tanaka, Akira Mitsuhashi, Katsuyoshi Seki, Souei Sekiya.   

Abstract

OBJECTIVES: To evaluate the spontaneous regression curve of serum human chorionic gonadotropin (hCG) in patients with an uneventful course after evacuation of hydatidiform mole and to compare the criteria for initiating chemotherapy in patients after evacuation of mole.
METHODS: From 1986 to 2001, 608 patients were followed at our department after evacuation of mole. The spontaneous regression curves of serum hCG in 432 patients with an uneventful course were established.
RESULTS: After evacuation of mole, the titers of serum hCG decreased constantly, and 90% of patients with an uneventful course were within normal range within 16 weeks. In 432 patients with an uneventful course, the upper 95% confidence limit of serum hCG at 5, 8 and 20 weeks was 753.7, 422.9 and 14.8 mIU/ml, respectively. Moreover, 39 (9.0%) and 15 patients (3.5%) with an uneventful course might have been diagnosed with gestational trophoblastic tumor and received needless chemotherapy based on the normal regression curve established by the Japan Society of Obstetrics and Gynecology or the US criteria of 4 consecutive plateauing or rising hCG values, respectively.
CONCLUSIONS: Our more selective criteria for initiating chemotherapy in patients after evacuation of mole, i.e. hCG of 10,000 mIU/ml at 5 weeks, 1,000 mIU/ml at 8 weeks and nondetectable levels at 24 weeks after evacuation of mole, may be safe and acceptable in the management of patients after evacuation of mole. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610317     DOI: 10.1159/000073843

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  1 in total

1.  Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy.

Authors:  Allison A Gockley; Lawrence H Lin; Michelle Davis; Alexander Melamed; Anthony Rizzo; Sue Yazaki Sun; Kevin Elias; Donald P Goldstein; Ross S Berkowitz; Neil S Horowitz
Journal:  Clinics (Sao Paulo)       Date:  2021-08-27       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.